EFG Asset Management North America Corp. Has $9.10 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

EFG Asset Management North America Corp. increased its holdings in shares of Glaukos Co. (NYSE:GKOS) by 106.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,592 shares of the medical instruments supplier’s stock after acquiring an additional 31,273 shares during the period. Glaukos comprises approximately 1.2% of EFG Asset Management North America Corp.’s holdings, making the stock its 9th largest holding. EFG Asset Management North America Corp. owned approximately 0.11% of Glaukos worth $9,102,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. IFP Advisors Inc bought a new position in shares of Glaukos in the fourth quarter worth about $43,000. Asset Planning Inc acquired a new stake in shares of Glaukos in the fourth quarter valued at approximately $90,000. Picton Mahoney Asset Management bought a new position in Glaukos in the 4th quarter worth approximately $125,000. Harvest Fund Management Co. Ltd lifted its holdings in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in Glaukos in the 4th quarter valued at $153,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GKOS. Stephens upgraded Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group started coverage on shares of Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Wells Fargo & Company increased their price objective on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, BTIG Research lifted their target price on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Stock Performance

Shares of Glaukos stock opened at $107.72 on Tuesday. Glaukos Co. has a 12 month low of $87.59 and a 12 month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $6.09 billion, a PE ratio of -37.53 and a beta of 0.99. The stock’s fifty day simple moving average is $134.44 and its 200 day simple moving average is $136.45.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. On average, research analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

Insider Activity

In other news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.